These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17582571)

  • 1. Dengue vaccines approach the finish line.
    Edelman R
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S56-60. PubMed ID: 17582571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dengue vaccines].
    Morita K
    Nihon Rinsho; 2008 Oct; 66(10):1999-2003. PubMed ID: 18939503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.
    Jones T
    Curr Opin Mol Ther; 2004 Aug; 6(4):443-50. PubMed ID: 15468603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding dengue pathogenesis: implications for vaccine design.
    Stephenson JR
    Bull World Health Organ; 2005 Apr; 83(4):308-14. PubMed ID: 15868023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
    Melino S; Paci M
    FEBS J; 2007 Jun; 274(12):2986-3002. PubMed ID: 17509079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue and yellow fever--challenges for the development and use of vaccines.
    Monath TP
    N Engl J Med; 2007 Nov; 357(22):2222-5. PubMed ID: 18046026
    [No Abstract]   [Full Text] [Related]  

  • 9. Using recombinant DNA technology for the development of live-attenuated dengue vaccines.
    Lee HC; Butler M; Wu SC
    Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue vaccine: opportunities and challenges.
    Hatch S; Mathew A; Rothman A
    IDrugs; 2008 Jan; 11(1):42-5. PubMed ID: 18175262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of dengue virus and the development of a vaccine.
    Murrell S; Wu SC; Butler M
    Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue vaccine.
    Simasathien S; Watanaveeradej V
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S363-77. PubMed ID: 16858980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress on sanofi pasteur's dengue vaccine candidate.
    Lang J
    J Clin Virol; 2009 Oct; 46 Suppl 2():S20-4. PubMed ID: 19800562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tropical diseases. Hunt for dengue vaccine heats up as the disease burden grows.
    Normile D
    Science; 2007 Sep; 317(5844):1494-5. PubMed ID: 17872423
    [No Abstract]   [Full Text] [Related]  

  • 16. Dengue vaccines for travelers.
    Wilder-Smith A; Deen JL
    Expert Rev Vaccines; 2008 Jul; 7(5):569-78. PubMed ID: 18564012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue fever climbs the social ladder.
    Nature; 2007 Aug; 448(7155):734-5. PubMed ID: 17700664
    [No Abstract]   [Full Text] [Related]  

  • 18. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
    Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
    Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplacentally transferred maternal-infant antibodies to dengue virus.
    Watanaveeradej V; Endy TP; Samakoses R; Kerdpanich A; Simasathien S; Polprasert N; Aree C; Vaughn DW; Ho C; Nisalak A
    Am J Trop Med Hyg; 2003 Aug; 69(2):123-8. PubMed ID: 13677366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.